We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
Read MoreHide Full Article
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) announced that its phase III study, evaluating JZP-110 has completed patient enrollment. The study is evaluating JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy.
The phase III narcolepsy study is a double-blind, placebo-controlled, multiple-center study, which enrolled 240 patients. The Maintenance of Wakefulness Test and the Epworth Sleepiness Scale were the co-primary endpoints. These measure the patient’s ability to stay awake and the severity of ES in them.
JZP-110 is also being evaluated in two phase III studies for the treatment of ES associated with obstructive sleep apnea (OSA).
The company expects to report positive results from the OSA studies in the first quarter of 2017 and from the narcolepsy study in the second quarter of 2017. Positive data from these studies would allow the company to file for approval in late 2017.
JZP-110, which enjoys Orphan Drug designation in the U.S. for narcolepsy, complements Jazz’s existing sleep disorder portfolio. According to the company, there is significant unmet need in narcolepsy and OSA with about 175–300K patients having an inadequate response to current wake-promoting therapies. More than 50% of patients fail one or more stimulants or wake-promoting agents. Data generated on JZP-110 looks good so far.
In Sep 2016, Jazz announced the completion of patient enrollment in the two OSA phase III studies.
Jazz is a Zacks Rank #3 (Hold) stock. The company’s share price is down almost 1.5%, while the medical drugs market is up at 8.74% in the last one month. Some better-ranked stocks in the healthcare sector include Heska Corporation , Arbutus Biopharma Corporation (ABUS - Free Report) and Anika Therapeutics Inc. (ANIK - Free Report) . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 69.60% year to date for the company.
Arbutus’ loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika’s earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) announced that its phase III study, evaluating JZP-110 has completed patient enrollment. The study is evaluating JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy.
The phase III narcolepsy study is a double-blind, placebo-controlled, multiple-center study, which enrolled 240 patients. The Maintenance of Wakefulness Test and the Epworth Sleepiness Scale were the co-primary endpoints. These measure the patient’s ability to stay awake and the severity of ES in them.
JZP-110 is also being evaluated in two phase III studies for the treatment of ES associated with obstructive sleep apnea (OSA).
The company expects to report positive results from the OSA studies in the first quarter of 2017 and from the narcolepsy study in the second quarter of 2017. Positive data from these studies would allow the company to file for approval in late 2017.
JZP-110, which enjoys Orphan Drug designation in the U.S. for narcolepsy, complements Jazz’s existing sleep disorder portfolio. According to the company, there is significant unmet need in narcolepsy and OSA with about 175–300K patients having an inadequate response to current wake-promoting therapies. More than 50% of patients fail one or more stimulants or wake-promoting agents. Data generated on JZP-110 looks good so far.
In Sep 2016, Jazz announced the completion of patient enrollment in the two OSA phase III studies.
JAZZ PHARMACEUT Price
JAZZ PHARMACEUT Price | JAZZ PHARMACEUT Quote
Jazz is a Zacks Rank #3 (Hold) stock. The company’s share price is down almost 1.5%, while the medical drugs market is up at 8.74% in the last one month. Some better-ranked stocks in the healthcare sector include Heska Corporation , Arbutus Biopharma Corporation (ABUS - Free Report) and Anika Therapeutics Inc. (ANIK - Free Report) . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 69.60% year to date for the company.
Arbutus’ loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika’s earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>